FEATURES OF PHARMACOTHERAPY OF LIVER DISEASES. ADVANTAGES AND DISADVANTAGES OF AVAILABLE HEPATOPROTECTIVE AGENTS
DOI:
https://doi.org/10.32782/health-2023.3.14Keywords:
hepatoprotectors, phospholipids, amino acids, hepatoprotectors based on plant raw materials, artificial molecules, side effects, contraindicationsAbstract
The article describes the features of pharmacotherapy of patients with liver disease. The pharmaceutical market of Ukraine, namely drugs of group A05B "Drugs used in case of liver diseases, lipotropic drugs" was analyzed. It has been established that currently 63 registered medicinal products belong to essential phospholipids, preparations based on medicinal plant raw materials, dressings based on amino acids, synthetic medicinal products and others. The percentage ratio of domestic / foreign production, original drugs/generics was analyzed. It has been proven that any hepatoprotector has certain features (pharmacokinetics, pharmacodynamics, side effects, contraindications) which are structured in the publication and which should be taken into account when recommending this group of drugs.
References
P. Caraceni, V. Vargas, E. Solà. Liverhope Consortium. The use of rifaximin in patients with cirrhosis. Hepatology. 2021. Vol. 74(3). P. 1660-1673.
Murag S. Recent Epidemiology of Nonalcoholic Fatty Liver Disease / S. Murag, A. Ahmed, D. Kim. Gut Liver. 2021. Vol. 15(2). P. 206-216.
Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study / A. M. Allen, T. M. Therneau, J. J. Larson at al. Hepatology. 2018. Vol. 67. P. 1726-1736.
Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening / R. Lomonaco, E. Godinez Leiva, F. Bril et al. Diabetes Care. 2021. Vol. 44(2). P. 399-406.
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis / Z. M. Younossi, P. Golabi, L. de Avila et al. Hepatology. 2019. Vol. 71. P. 793-801.
American Diabetes Association; 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020. Diabetes Care. 1 January 2020; Vol. 43 (Supplement_1). S. 37–S47. DOI: https://doi.org/10.2337/dc20-S004
Budd J.? Cusi K. Nonalcoholic fatty liver disease: what does the primary care physician need to know ? Am. J. Med. 2020. Vol. 133. P. 536–543.
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study / Y. J. Wong, M. H. Zheng, E. Barnes, A. S. Barritt 4th, G. J. Webb/ Hepatology. 2021. Vol. 74(3). P. 567-577.
Tongji multidisciplinary team for treating COVID-19 (TTTC). Association of liver abnormalities with in-hospital mortality in patients with COVID-19 / Z. Y. Ding, G. X. Li, L. Chen et al. Hepatology. 2021. Vol. 74(6). P. 1295-1302.
Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study / D. Kim, N. Adeniji, N. Latt et al. Clin Gastroenterol Hepatol. 2021. Vol. 19(7). P. 1469-1479.
Державний реєстр лікарських засобів України. URL: http://driz.com.ua
Dajani A.I., Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. Affiliations expand. 2020. Vol. 8(21). P. 5235–5249.
Correlation of objective endpoints and subjective patient-reported outcomes in NAFLD treatment with essential phospholipids: real-world data based on pooled analysis of observational studies / V. T. Ivashkin, M. V. Maevskaya, E. N. Shirokova et al. Affiliations expand. 2021. Vol. 8(3). P. 369–382.
Federico A., Dallio M., Loguercio C. Silymarin/Silybin and chronic liver disease: a marriage of many years. Affiliations expand. 2017. Vol. 22(2). P. 191. DOI: 10.3390/molecules22020191.
Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases / L. Abenavoli, A. A. Izzo, N. Milić, C. Cicala, A. Santini, R. Capasso. Affiliations expand. 2018. Vol. 32(11). P. 2202–2213.
Highly bioavailable silibinin nanoparticles inhibit HCV infection / C. Liu, C. Lin, W. Hsu et al. Affiliations expand. 2017. Vol. 66(10). P. 1853–1861.
Silibinin Improves TNF-α and M30 Expression and Histological Parameters in Rat Kidneys After Hepatic Ischemia/ Reperfusion / G. Kyriakopoulos, A. K. Tsaroucha, G. Valsami et al. Affiliations expand. 2018. Vol. 31(3). P. 201–209.
Silychristin derivatives conjugated with coniferylalcohols from silymarin and their pancreatic α-amylase inhibitory activity / E. Kato, N. Kushibiki, H. Satoh, J. Kawabata. Nat Prod Res. 2020. Vol. 34(6). P. 759–765.
Tsikas D., Hanff E., Bollenbach A. S-Adenosyl-L-methionine towards hepatitis C virus expression: Need to consider S-Adenosyl-L-methionine's chemistry, physiology and pharmacokinetics. Affiliations expand. 2017. Vol. 23(40). P. 7343–7346.
Інструкція з медичного застосування лікарського препарату «Антраль». URL: https://compendium.com.ua/info/146719/antral_-sup-sup-/
The Health Effects of Aluminum Exposure / K. Klotz, W. Weistenhöfer, F. Neff, A. Hartwig, C. van Thriel, H. Drexler. Dtsch Arztebl Int. 2017. Vol. 114(39). P. 653-659.
Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts / C. C. Willhite, N. A. Karyakina, R. A. Yokel et al. Crit Rev Toxicol. 2014. Vol. 4. P. 1-80. DOI: 10.3109/10408444.2014.934439.
